NewsRoom Articles - Page 477 of 1442

TuesdayJul 20, 2021 9:00 am

Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) Leverages Genetic Technology to Produce First-In-Class Medical Grade Cannabis

Science continues to substantiate use of cannabis for pain relief, epileptic seizure control Research suggests strains with optimized cannabinoid profiles are more effective PACR produces premium top-quality strains cultivated using genetics-first approach to optimize cannabinoid profiles Genetic cultivation techniques allow selection for specific growing environments, maximum yields With a growing list of use cases spanning pain relief to seizure control, the medicinal use of cannabis goes back thousands of years (https://nnw.fm/3LSGh). Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canadian cannabis company, leverages a genetics-focused approach to producing premium-quality strains with optimum cannabinoid profiles that are prized among…

TuesdayJul 20, 2021 7:00 am

Mobius Interactive Ltd.’s Deep Dive into the Latin American iGaming Market

The Mobius Interactive flagship brand, Mobius.bet, is a top sponsor for the next six matches of the 2021 FIFA World Cup Soccer Qualifiers in Brazil The Mobius.bet brand will be showcased on Globo TV Brazil, attracting 35 – 40 million viewers per match By partnering with Globo TV, Mobius Interactive will reach more sports enthusiasts, showcasing the Mobius.bet brand and growing its market reach Mobius Interactive has signed a lucrative sponsorship agreement to display its flagship brand, Mobius.bet, on national TV in Brazil for the 2021 FIFA World Cup Qualifiers, marking the company’s entry into the expanding Brazilian iGaming industry.…

MondayJul 19, 2021 12:47 pm

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Leverages Pandemic-Induced Trends, Changes in the Food & Beverage Industry Through Strategic Partnerships

PlantX Life recently launched as a seller on both Walmart Canada Marketplace and Hudson’s Bay Marketplace The launches appear to be leveraging the changes and trends brought about by the COVID-19 pandemic In addition, the agreements are part of PlantX’s growth strategy The company will offer thousands of its products on both platforms As the COVID-19 pandemic upended multiple aspects of life in Canada, it did not spare the retail industry. Here, it forced Canadians to rethink how, where and when they shop, with the paramount consideration in their decision-making process being their personal and family health and safety. Shopping…

MondayJul 19, 2021 11:23 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting and investor relations services Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp…

MondayJul 19, 2021 11:03 am

FingerMotion Inc. (FNGR) Tackling the Market Through Unmatched Innovation and Technology

FingerMotion’s strategy is to rapidly expand its user base through organic means utilizing a broad range of innovative applications It handles over 500,000 transactions every day for its mobile payment and recharge service, all facilitated by superior technology Technology and innovation are at the center of FingerMotion’s operations and activities and will clearly play a significant role in the company’s future FingerMotion (OTCQX: FNGR), since its inception back in 2016, has always pushed boundaries with innovation and introducing new ideas. Innovation has always played a central role in what the company does, and it leverages this to expand its market…

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://nnw.fm/NRSG5). "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

MondayJul 19, 2021 9:30 am

Golden Triangle Ventures Inc. (GTVH) Working to Develop, Commercialize First-of-Its-Kind Technology

GTVH, HyFrontier Technologies working together to offer a patent-pending hydrogen and oxygen delivery system for agriculture. Company has seen recent developments that could significantly benefit the entire agricultural industry. Duplicating enhanced-growth thunderstorms cause can reduce need for crop rotations, helping millions of people avoid starvation. A little more than a month after announcing its formal purchase agreement with HyFrontier Technologies (https://nnw.fm/HApVT), Golden Triangle Ventures (OTC: GTVH) is making good on its commitment to pursue ventures in the technology sector to provide advanced technology for the modern era. GTVH and HyFrontier Technologies are working together to offer a patent-pending, first-of-its-kind hydrogen…

MondayJul 19, 2021 9:00 am

DealMaker Webinar Features Industry Experts, Takes Closer Look at Reg A+ Distribution Channels

Industry experts share expertise, insight in next DealMaker webinar. Successful Reg A+ offerings tell their stories across multiple mediums. DealMaker is building a reputation for its ability to offer services that support companies across a wide array of needs. With its mission of delivering speed, innovation and efficiency to global capital markets in mind, DealMaker has scheduled its next webinar. Slated for July 20, 2021, at 12 noon ET, the event will feature Don Yocham, executive director of the National Institute of Cannabis Investors, and Ryan Bradford, director of digital marketing at Creative Direct Marketing Group as well as DealMaker’s…

MondayJul 19, 2021 9:00 am

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Reports Successful Implementation and Testing of HealthTab(TM) in Shoppers Drug Mart(R) Locations

The program’s initial focus is to support those at risk or already diagnosed with diabetes or cardiovascular disease, offering better health management and quality of life In the United States, approximately 88 million adults live with prediabetes, and as many as 84% do not know they have it. It is estimated that by 2030, 13.6 million Canadians will be diabetic or prediabetic The global point-of-care diagnostics testing market was valued at $30.45 billion in 2021 and is anticipated to grow at a CAGR of 3.25%, resulting in a revenue forecast of $35.74 billion by 2028 Avricore Health Inc. (TSX.V:…

FridayJul 16, 2021 1:47 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…

Financial news and publishing for public and private companies

Contact us: 512.354.7000